Structure Therapeutics, Inc. (GPCR)
64.80
-2.26
(-3.37%)
USD |
NASDAQ |
Dec 15, 16:00
64.82
+0.02
(+0.03%)
Pre-Market: 08:16
Structure Therapeutics Research and Development Expense (Quarterly): 59.07M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 3.466B |
| Novo Nordisk A/S | 2.410B |
| Pfizer Inc. | 2.492B |
| Viking Therapeutics, Inc. | 89.95M |
| Altimmune, Inc. | 14.93M |